FDA Approves Daratumumab for Newly Diagnosed, Transplant Ineligible MM Patients

On May 7, 2018, the Food and Drug Administration approved daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma (MM) who are ineligible for autologous stem cell transplant (ASCT).

Read the Johnson & Johnson press release here.

Posted 5/8/2018